CBP/p300-IN-10

• CAT Number: I042667
• CAS Number: 2259641-71-7
• Molecular Formula: C25H24F5N5O3
• Molecular Weight: 537.48
• Purity: ≥95%
• Synonyms: (2R,4R)-1-[1-[4-(difluoromethoxy)phenyl]-4,4-difluorocyclohexanecarbonyl]-4-fluoro-N-(1H-pyrazolo[4,3-b]pyridin-5-yl)pyrrolidine-2-carboxamide
• InChI: InChI=1S/C25H24F5N5O3/c26-15-11-19(21(36)33-20-6-5-17-18(32-20)12-31-34-17)35(13-15)22(37)24(7-9-25(29,30)10-8-24)14-1-3-16(4-2-14)38-23(27)28/h1-6,12,15,19,23H,7-11,13H2,(H,31,34)(H,32,33,36)/t15-,19-/m1/s1
• InChIKey: IGBIPTRCWSVZCO-DNVCBOLYSA-N
• SMILES: C1CC(CCC1(C2=CC=C(C=C2)OC(F)F)C(=O)N3C[C@@H](C[C@@H]3C(=O)NC4=NC5=C(C=C4)NN=C5)F)(F)F

CBP/p300-IN-10（Cat No.:I042667）is an investigational small molecule inhibitor designed to target the CBP (CREB-binding protein) and p300, two closely related transcriptional coactivators that play a crucial role in regulating gene expression and cellular processes. These proteins are involved in various cellular functions, including cell growth, differentiation, and response to stress, and are implicated in cancer, neurodegenerative diseases, and other conditions. By inhibiting CBP/p300, CBP/p300-IN-10 aims to disrupt abnormal gene expression patterns and potentially treat diseases driven by dysregulated transcription. Ongoing research focuses on its efficacy, safety, and therapeutic potential in various disease models.